PEN — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-07-30

• We generated revenue of $390.0 million and $339.5 million for the three months ended June 30, 2026 and 2025, respectively, an increase of $50.6 million, and revenue of $764.8 million and $663.6 million for the six months ended June 30, 2026 and 2025, respectively, an increase of $101.2 million. We g…

• Six Months Ended June 30, 2026 Compared to the Six Months Ended June 30, 2025

• Revenue increased $101.2 million, or 15.3%, to $764.8 million in the six months ended June 30, 2026, from $663.6 million in the six months ended June 30, 2025. Overall revenue growth was primarily due to an increase in sales of our existing thrombectomy products and new and existing embolization and…

• Revenue from our global thrombectomy products increased $56.1 million, or 12.3%, to $512.9 million in the six months ended June 30, 2026, from $456.8 million in the six months ended June 30, 2025. The increase in our global thrombectomy products was primarily attributable to higher sales volume in t…

• Revenue from our global embolization and access products increased $45.1 million, or 21.8%, to $251.9 million in the six months ended June 30, 2026, from $206.8 million in the six months ended June 30, 2025. The increase in our global embolization and access products was primarily attributable to hi…

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• We generated revenue of $374.8 million and $324.1 million for the three months ended March 31, 2026 and 2025, respectively, an increase of $50.6 million. We generated income from operations of $38.2 million and $40.4 million for the three months ended March 31, 2026 and 2025, respectively.

• As of March 31, 2026, we had $1,063.7 million in working capital, which included $241.3 million in cash and cash equivalents and $374.4 million in marketable investments. As of March 31, 2026, we held approximately 10.8% of our cash and cash equivalents in foreign entities.

• Net cash provided by operating activities was $87.0 million during the three months ended March 31, 2026 and consisted of consolidated net income of $32.6 million, non-cash items of $18.9 million, and net changes in operating assets and liabilities of $35.5 million. The change in operating assets an…

• Net cash (used in) provided by financing activities primarily relates to payments of employee taxes related to vested restricted stock units and payments towards the reduction of our finance lease obligations, offset by proceeds from exercises of stock options.

Text added vs the prior filing · source: 10-Q · 2026-07-30

• During the quarterly period ended June 30, 2026, no director or officer adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408(a) of Regulation S-K.

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• During the quarterly period ended March 31, 2026, certain of our directors and officers terminated trading plans, each of which was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (the “Rule 10b5-1 Trading Arrangements”). The following table presents t…

• Johanna Roberts, Executive Vice President, General Counsel and Secretary

• (1)As of the termination date of his Rule 10b5-1 Trading Arrangement, Dr. Bose had not sold any shares of common stock under the terms thereof.

• (2)As of the termination date of his Rule 10b5-1 Trading Arrangement, Mr. Elsesser had not sold any shares of common stock under the terms thereof.

• (3)As of the termination date of her Rule 10b5-1 Trading Arrangement, Ms. O’Rourke had not sold any shares of common stock under the terms thereof.